Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133242 | 0.98 | CYP3A4 (0.40) | CYP3A4SMN1; SMN2ALDH1A1LMNACYP2C19 | |
| Hydrochloric Acid SCHEMBL28097210 | 0.95 | CYP3A4 (0.39) | CYP3A4SMN1; SMN2ALDH1A1LMNACYP2C19 | |
| SCHEMBL1515612 | 0.95 | — | — | |
| SCHEMBL2060504 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL19900778 | 0.87 | — | — | |
| SCHEMBL18934852 | 0.79 | KDM4E (0.48) | CYP1A2KDM4EKMT2A | |
| SCHEMBL1515589 | 0.79 | CTSC (0.37) | ALDH1A1LMNACTSCKCNH2 | |
| SCHEMBL21661391 | 0.78 | KDM4E (0.35) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL20837330 | 0.77 | DGAT1 (0.43) | CYP3A4ALDH1A1LMNACYP2C19CHRM3 | |
| SCHEMBL3107018 | 0.75 | HDAC4 (0.42) | CYP3A4ALDH1A1LMNACYP2C19CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220402841-A1 | Stilbene Derivative and Method for Preparing Same | Ozchela Inc. (KR) | 2022-12-22 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| CN-110709085-A | Compounds and methods for treating visceral pain | 艾尼纳制药公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190255009-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | OZCHELA INC (KR) | 2019-08-22 | — | — | US | disclosed |
| US-20190248729-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | Ozchela Inc. (KR) | 2019-08-15 | — | — | US | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9944606-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CYP3A4 2898/4885SMN1; SMN2 208/4885ALDH1A1 3623/4885 |
| US-20190255009-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | HPN, P4HB, FKBP1B | CYP3A4 460/4885SMN1; SMN2 1141/4885ALDH1A1 174/4885 |
| US-20220402841-A1 | Stilbene Derivative and Method for Preparing Same | FKBP1B, FKBP8, FKBP2 | CYP3A4 1531/4885SMN1; SMN2 1618/4885ALDH1A1 1073/4885 |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | CYP3A4 3301/4885SMN1; SMN2 3930/4885ALDH1A1 603/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CYP3A4 2898/4885SMN1; SMN2 208/4885ALDH1A1 3623/4885 |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CYP3A4 686/4885SMN1; SMN2 3382/4885ALDH1A1 1759/4885 |
| US-20190248729-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | FKBP1B, FKBP8, FKBP2 | CYP3A4 1531/4885SMN1; SMN2 1618/4885ALDH1A1 1073/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | CYP3A4 2898/4885SMN1; SMN2 208/4885ALDH1A1 3623/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | CYP3A4 2898/4885SMN1; SMN2 208/4885ALDH1A1 3623/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | CYP3A4 3301/4885SMN1; SMN2 3930/4885ALDH1A1 603/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CYP3A4 2898/4885SMN1; SMN2 208/4885ALDH1A1 3623/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CYP3A4 2898/4885SMN1; SMN2 208/4885ALDH1A1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.